Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small-cell lung cancer (NSCLC)

被引：1
|
作者：
Grossi, F. [1 ]
Brianti, A. [1 ]
Defferrari, C. [1 ]
Dal Bello, M. G. [1 ]
Loprevite, M. [1 ]
Catania, G. [1 ]
Pronzato, P. [1 ]
机构：
[1] Natl Inst Canc Res, Genoa, Italy
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71453-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6625
引用
收藏
页码：395 / 395
页数：1
相关论文
共 50 条
  • [1] Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small-cell lung cancer (NSCLC)
    Defferrari, C.
    Brianti, A.
    Dal Bello, M. G.
    Loprevite, M.
    Catania, G.
    Pronzato, P.
    Grossi, F.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 24 - 24
  • [2] Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small cell lung cancer (NSCLC)
    Grossi, F.
    Brianti, A.
    Defferrari, C.
    Loprevite, M.
    Catania, G.
    Pronzato, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Skin toxicities difference between erlotinib (E) and gefitinib (G) in the treatment of advanced non-small-cell lung cancer (NSCLC)
    Brianti, A.
    Defferrari, C.
    Dal Bello, M. G.
    Loprevite, M.
    Catania, G.
    Grossi, F.
    Pronzato, P.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 28 - 28
  • [4] DIFFERENCE IN SKIN TOXICITY INCIDENCE BETWEEN ERLOTINIB (E) AND GEFITINIB (G) IN THE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Grossi, F.
    Defferrari, C.
    Brianti, A.
    Dal Bello, M. G.
    Catania, G.
    Pronzato, P.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 106 - 107
  • [5] Erlotinib in advanced non-small-cell lung cancer after gefitinib failure
    Zheng-Tao Zhou
    Xin-Hua Xu
    Qing Wei
    Ming-qian Lu
    Jie Wang
    Cai-Hong Wen
    [J]. Cancer Chemotherapy and Pharmacology, 2009, 64 : 1123 - 1127
  • [6] Erlotinib in advanced non-small-cell lung cancer after gefitinib failure
    Zhou, Zheng-Tao
    Xu, Xin-Hua
    Wei, Qing
    Lu, Ming-qian
    Wang, Jie
    Wen, Cai-Hong
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (06) : 1123 - 1127
  • [7] Comparison of Gefitinib and Erlotinib for Patients with Advanced Non-Small-Cell Lung Cancer
    Lee, Jin Hwa
    Lee, Kyoung Eun
    Ryu, Yon Ju
    Chun, Eun Mi
    Chang, Jung Hyun
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2009, 66 (04) : 280 - 287
  • [8] ERLOTINIB (E) TREATMENT AFTER FAILURE OF GEFITINIB (G) IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS PREVIOUSLY RESPONDING TO EGFR TYROSINE KINASE INHIBITORS (TKI)
    Vasile, E.
    Tibaldi, C.
    Chella, A.
    Lo Dico, M.
    Mazzoni, E.
    D'Incecco, A.
    Di Giulio, A.
    Ambrosino, N.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 103 - 104
  • [9] The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib
    Grossi, Francesco
    Rijavec, Erika
    Dal Bello, Maria Giovanna
    Defferrari, Carlotta
    Brianti, Annalisa
    Barletta, Giulia
    Genova, Carlo
    Murolo, Carmelina
    Cosso, Maurizio
    Fontanini, Gabriella
    Boldrini, Laura
    Truini, Mauro
    Pronzato, Paolo
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1407 - 1412
  • [10] Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer
    Passaro, Antonio
    Alesini, Daniele
    Pochesci, Alessia
    Cortesi, Enrico
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (05) : 646 - 650
12345